Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM)

NCT07771361 is registered in ClinicalTrials.gov with Luminary Therapeutics as lead sponsor.

NCT NCT07771361
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07771361 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM)
Lead sponsor
Luminary Therapeutics
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
February 28, 2031
Enrollment
90 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma (mm), lymphoma, large b-cell, diffuse (dlbcl), lymphoma, multiple myeloma in relapse, multiple myeloma in remission, multiple myeloma refractory, non-hodgkin lymphoma, non-hodgkin lymphoma (nhl), non-hodgkin lymphoma refractory/ relapsed, non-hodgkin lymphoma, b-cell